These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 19734429)

  • 1. Detection of twelve nucleotides insertion in the BCR-ABL kinase domain in an imatinib-resistant but dasatinib-sensitive patient with bi-phenotypic acute leukemia.
    Hayette S; Chabane K; Tchirkov A; Berger MG; Nicolini FE; Tournilhac O
    Haematologica; 2009 Sep; 94(9):1324-6. PubMed ID: 19734429
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
    Jabbour E; Jones D; Kantarjian HM; O'Brien S; Tam C; Koller C; Burger JA; Borthakur G; Wierda WG; Cortes J
    Blood; 2009 Sep; 114(10):2037-43. PubMed ID: 19567878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
    Ernst T; Gruber FX; Pelz-Ackermann O; Maier J; Pfirrmann M; Müller MC; Mikkola I; Porkka K; Niederwieser D; Hochhaus A; Lange T
    Haematologica; 2009 Sep; 94(9):1227-35. PubMed ID: 19608684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.
    Soverini S; Gnani A; Colarossi S; Castagnetti F; Abruzzese E; Paolini S; Merante S; Orlandi E; de Matteis S; Gozzini A; Iacobucci I; Palandri F; Gugliotta G; Papayannidis C; Poerio A; Amabile M; Cilloni D; Rosti G; Baccarani M; Martinelli G
    Blood; 2009 Sep; 114(10):2168-71. PubMed ID: 19589924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy.
    Hanfstein B; Müller MC; Kreil S; Ernst T; Schenk T; Lorentz C; Schwindel U; Leitner A; Hehlmann R; Hochhaus A
    Haematologica; 2011 Mar; 96(3):360-6. PubMed ID: 21134983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells.
    Wu J; Meng F; Ying Y; Peng Z; Daniels L; Bornmann WG; Quintás-Cardama A; Roulston D; Talpaz M; Peterson LF; Donato NJ
    Leukemia; 2010 Apr; 24(4):869-72. PubMed ID: 20111070
    [No Abstract]   [Full Text] [Related]  

  • 7. Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
    Jabbour E; Cortes J; Kantarjian H
    Expert Opin Investig Drugs; 2007 May; 16(5):679-87. PubMed ID: 17461740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.
    Shah NP; Kim DW; Kantarjian H; Rousselot P; Llacer PE; Enrico A; Vela-Ojeda J; Silver RT; Khoury HJ; Müller MC; Lambert A; Matloub Y; Hochhaus A
    Haematologica; 2010 Feb; 95(2):232-40. PubMed ID: 20139391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Stock W
    Leuk Lymphoma; 2010 Feb; 51(2):188-98. PubMed ID: 20001232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical progress in chronic myelogenous leukemia].
    Matsunaga T
    Rinsho Ketsueki; 2009 Oct; 50(10):1489-99. PubMed ID: 19915358
    [No Abstract]   [Full Text] [Related]  

  • 12. New strategies in controlling drug resistance in chronic myeloid leukemia.
    Frame D
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S16-21. PubMed ID: 18056927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
    Cortes J; Rousselot P; Kim DW; Ritchie E; Hamerschlak N; Coutre S; Hochhaus A; Guilhot F; Saglio G; Apperley J; Ottmann O; Shah N; Erben P; Branford S; Agarwal P; Gollerkeri A; Baccarani M
    Blood; 2007 Apr; 109(8):3207-13. PubMed ID: 17185463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing second-line therapy for chronic myeloid leukemia.
    Raja T
    Indian J Cancer; 2012; 49(1):46-56. PubMed ID: 22842168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chronic myeloid leukemia: up-to-date management].
    Nakayama K; Inokuchi K
    Rinsho Ketsueki; 2014 Jan; 55(1):42-55. PubMed ID: 24492036
    [No Abstract]   [Full Text] [Related]  

  • 17. [Management of chronic myeloid leukemia].
    Kubuki Y
    Rinsho Ketsueki; 2008 Oct; 49(10):1401-10. PubMed ID: 18833925
    [No Abstract]   [Full Text] [Related]  

  • 18. Dasatinib induces a response in chronic lymphocytic leukemia.
    Pitini V; Arrigo C; Altavilla G
    Blood; 2009 Jan; 113(2):498. PubMed ID: 19131559
    [No Abstract]   [Full Text] [Related]  

  • 19. AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance.
    Azam M; Powers JT; Einhorn W; Huang WS; Shakespeare WC; Zhu X; Dalgarno D; Clackson T; Sawyer TK; Daley GQ
    Chem Biol Drug Des; 2010 Feb; 75(2):223-7. PubMed ID: 20028401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib overrides imatinib resistance mediated by the F359I residue mutation in two patients with chronic myeloid leukemia.
    Serpa M; Sanabani SS; Dorlhiac-Llacer PE; Nardinelli L; de Barros Ferreira P; Martins TF; Seguro F; Bendit I
    Acta Haematol; 2012; 127(1):56-9. PubMed ID: 22094354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.